XENE Stock Analysis: Xenon Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 5.893m USD | 12M Return: 99.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 81.0M
Qual. Beats: 0
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is a clinical-stage, neuroscience-focused biopharmaceutical company headquartered in Burnaby, Canada, that develops therapeutics for neurological and psychiatric disorders. Founded in 1996 and listed on NASDAQ since 2014, the company operates as a small-cap biotech within the Health Care sector, relying on equity capital and partnerships to fund its drug development pipeline.
The companys lead candidate, Azetukalner, is a Kv7 potassium channel opener currently in Phase 3 clinical trials for epilepsy (focal onset seizures and primary generalized tonic-clonic seizures) and is also being evaluated in neuropsychiatric indications including major depressive disorder and bipolar depression. Earlier-stage assets include XEN1701 (sodium channel) and XEN1120 (Kv7 potassium channel), both in Phase 1 for pain.
Xenon supplements its internal pipeline through a license and collaboration agreement with Neurocrine Biosciences for NBI-921355, a Nav1.2/1.6 sodium channel inhibitor in Phase 1 development for certain forms of epilepsy - a partnership structure commonly used by clinical-stage biotechs to share development costs and expand pipeline reach.
- Azetukalner Phase 3 epilepsy data readout approaches
- Neurocrine collaboration delivers milestone revenue and validation
- Cash burn and runway concerns grow as clinical spending accelerates
| Net Income: -383.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.22 > 0.02 and ΔFCF/TA 4.93 > 1.0 |
| NWC/Revenue: 14.2k% < 20% (prev 5.33k%; Δ 8.90k% < -1%) |
| CFO/TA -0.22 > 3% & CFO -306.4m > Net Income -383.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 27.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (87.3m) vs 12m ago 11.00% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.70% > 50% (prev 1.35%; Δ -0.64% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.77 (Total Current Assets 1.11b - Total Current Liabilities 39.8m) / Total Assets 1.39b |
| B: -0.97 (Retained Earnings -1.35b / Total Assets 1.39b) |
| C: -0.38 (EBIT TTM -401.5m / Avg Total Assets 1.07b) |
| D: 27.31 (Book Value of Equity 1.34b / Total Liabilities 49.0m) |
| Altman-Z'' = 28.02 = AAA |
| DSRI: 0.18 (Receivables 1.17m/8.65m, Revenue 7.50m/10.0m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.89 (AQ_t 0.19 / AQ_t-1 0.22) |
| SGI: 0.75 (Revenue 7.50m / 10.0m) |
| TATA: -0.06 (NI -383.2m - CFO -306.4m) / TA 1.39b) |
| Beneish M = -3.95 (Cap -4..+1) = AAA |
As of July 08, 2026, the stock is trading at USD 63.37 with a total of 1,420,614 shares traded. Over the past week, the price has changed by +5.39%, over one month by +23.75%, over three months by +9.92% and over the past year by +99.09%.
Current recommended Stop Loss: 61.20 (which is 3.4% or 1.2 ATR below the current price).
Xenon Pharmaceuticals has received a consensus analysts rating of 4.74. Therefore, it is recommended to buy XENE.
- StrongBuy: 14
- Buy: 5
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 80.6 | 27.1% |
P/S = 727.4404
P/B = 4.357
P/EG = -0.06
Revenue TTM = 7.50m USD
EBIT TTM = -401.5m USD
EBITDA TTM = -399.0m USD
Long Term Debt = 5.93m USD (estimated: total debt 7.49m - short term 1.56m)
Short Term Debt = 1.56m USD (from shortTermDebt, last quarter)
Debt = 7.49m USD (from shortLongTermDebtTotal, last quarter) (leases 7.49m already included)
Net Debt = -1.09b USD (calculated: Debt 7.49m - CCE 1.09b)
Enterprise Value = 4.81b USD (5.89b + Debt 7.49m - CCE 1.09b)
Interest Coverage Ratio = unknown (Ebit TTM -401.5m / Interest Expense TTM 0.0)
EV/FCF = -15.64x (Enterprise Value 4.81b / FCF TTM -307.3m)
FCF Yield = -6.39% (FCF TTM -307.3m / Enterprise Value 4.81b)
FCF Margin = -4.10k% (FCF TTM -307.3m / Revenue TTM 7.50m)
Net Margin = -5.11k% (Net Income TTM -383.2m / Revenue TTM 7.50m)
Gross Margin = unknown ((Revenue TTM 7.50m - Cost of Revenue TTM 78.9m) / Revenue TTM)
Tobins Q-Ratio = 3.47 (Enterprise Value 4.81b / Total Assets 1.39b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 7.49m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -317.2m (EBIT -401.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 27.79 (Total Current Assets 1.11b / Total Current Liabilities 39.8m)
Debt / Equity = 0.01 (Debt 7.49m / totalStockholderEquity, last quarter 1.34b)
Debt / EBITDA = 2.72 (negative EBITDA) (Net Debt -1.09b / EBITDA -399.0m)
Debt / FCF = 3.54 (negative FCF - burning cash) (Net Debt -1.09b / FCF TTM -307.3m)
Total Stockholder Equity = 778.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -35.98% (Net Income -383.2m / Total Assets 1.39b)
RoE = -49.23% (Net Income TTM -383.2m / Total Stockholder Equity 778.3m)
RoCE = -51.20% (EBIT -401.5m / Capital Employed (Equity 778.3m + L.T.Debt 5.93m))
RoIC = -23.53% (negative operating profit) (NOPAT -317.2m / Invested Capital 1.35b)
WACC = 6.48% (E(5.89b)/V(5.90b) * Re(6.49%) + D(7.49m)/V(5.90b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 6.49% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 85.63 | Cagr: 12.31%
[DCF] Fair Price = unknown (Cash Flow -307.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.49 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.50 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.16 | Chg30d=+1.34% | Revisions=+21% | Analysts=14
EPS next Quarter (2026-09-30): EPS=-1.19 | Chg30d=+0.86% | Revisions=+36% | Analysts=14
EPS current Year (2026-12-31): EPS=-4.81 | Chg30d=+0.34% | Revisions=-6% | GrowthEPS=-10.3% | GrowthRev=-72.5%
EPS next Year (2027-12-31): EPS=-5.01 | Chg30d=-5.88% | Revisions=-31% | GrowthEPS=-4.1% | GrowthRev=+1602.7%
[Analyst] Revisions Ratio: +4% (up=25, down=23)